101 Massachusetts General Hospital (MGH) CRS
Welcome,         Profile    Billing    Logout  
 3 Trials 
7 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Gandhi, Rajesh T
NCT04636437: Doravirine for Persons With Excessive Weight Gain on Integrase Inhibitors and Tenofovir Alafenamide

Active, not recruiting
4
222
US
Doravirine 100 Mg, Tenofovir alafenamide/emtricitabine, tenofovir alafenamide/lamivudine, Integrase strand transfer inhibitors, tenofovir disproxil fumarate/emtricitabine, tenofovir disproxil fumarate/lamivudine
Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections, National Institute of Allergy and Infectious Diseases (NIAID)
HIV Infections
11/24
11/24
NCT03382834: Selective Estrogen Receptor Modulators to Enhance the Efficacy of Viral Reactivation With Histone Deacetylase Inhibitors

Completed
2
31
US
Tamoxifen, Vorinostat, Antiretroviral drugs
National Institute of Allergy and Infectious Diseases (NIAID)
HIV Infections
12/18
07/23
PURGE-C, NCT04042740: Glecaprevir/Pibrentasvir Fixed-dose Combination Treatment for Acute Hepatitis C Virus Infection

Completed
2
45
US, RoW
Glecaprevir/Pibrentasvir (G/P), Mavyret
Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections, AbbVie, National Institute of Allergy and Infectious Diseases (NIAID)
Hepatitis C Infection, HIV Infection
05/23
08/23
NCT05630885: A Study to Evaluate the Effects of Cenicriviroc Mesylate on Arterial Inflammation in People Living With HIV

Completed
2
110
US
CVC 150 mg, CVC 300 mg, Placebo for CVC 150 mg, Placebo for CVC 300 mg
National Institute of Allergy and Infectious Diseases (NIAID), AbbVie
HIV-1-infection
06/24
06/24
ACTIVATE, NCT02471430: Reducing the Residual Reservoir of HIV-1 Infected Cells in Patients Receiving Antiretroviral Therapy

Completed
1/2
17
US
Panobinostat, Farydak, LBH589, Pegylated Interferon-alpha2a, Pegasys
Massachusetts General Hospital, Novartis, Genentech, Inc.
HIV Infection
08/22
12/23
Flynn, Teri
PURGE-C, NCT04042740: Glecaprevir/Pibrentasvir Fixed-dose Combination Treatment for Acute Hepatitis C Virus Infection

Completed
2
45
US, RoW
Glecaprevir/Pibrentasvir (G/P), Mavyret
Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections, AbbVie, National Institute of Allergy and Infectious Diseases (NIAID)
Hepatitis C Infection, HIV Infection
05/23
08/23
NCT00031408: Consent for Use of Stored Patient Specimens for Future Testing

Recruiting
N/A
30000
US
Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections, National Institute of Allergy and Infectious Diseases (NIAID)
HIV Infections
12/27
12/27
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Gandhi, Rajesh T
NCT04636437: Doravirine for Persons With Excessive Weight Gain on Integrase Inhibitors and Tenofovir Alafenamide

Active, not recruiting
4
222
US
Doravirine 100 Mg, Tenofovir alafenamide/emtricitabine, tenofovir alafenamide/lamivudine, Integrase strand transfer inhibitors, tenofovir disproxil fumarate/emtricitabine, tenofovir disproxil fumarate/lamivudine
Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections, National Institute of Allergy and Infectious Diseases (NIAID)
HIV Infections
11/24
11/24
NCT03382834: Selective Estrogen Receptor Modulators to Enhance the Efficacy of Viral Reactivation With Histone Deacetylase Inhibitors

Completed
2
31
US
Tamoxifen, Vorinostat, Antiretroviral drugs
National Institute of Allergy and Infectious Diseases (NIAID)
HIV Infections
12/18
07/23
PURGE-C, NCT04042740: Glecaprevir/Pibrentasvir Fixed-dose Combination Treatment for Acute Hepatitis C Virus Infection

Completed
2
45
US, RoW
Glecaprevir/Pibrentasvir (G/P), Mavyret
Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections, AbbVie, National Institute of Allergy and Infectious Diseases (NIAID)
Hepatitis C Infection, HIV Infection
05/23
08/23
NCT05630885: A Study to Evaluate the Effects of Cenicriviroc Mesylate on Arterial Inflammation in People Living With HIV

Completed
2
110
US
CVC 150 mg, CVC 300 mg, Placebo for CVC 150 mg, Placebo for CVC 300 mg
National Institute of Allergy and Infectious Diseases (NIAID), AbbVie
HIV-1-infection
06/24
06/24
ACTIVATE, NCT02471430: Reducing the Residual Reservoir of HIV-1 Infected Cells in Patients Receiving Antiretroviral Therapy

Completed
1/2
17
US
Panobinostat, Farydak, LBH589, Pegylated Interferon-alpha2a, Pegasys
Massachusetts General Hospital, Novartis, Genentech, Inc.
HIV Infection
08/22
12/23
Flynn, Teri
PURGE-C, NCT04042740: Glecaprevir/Pibrentasvir Fixed-dose Combination Treatment for Acute Hepatitis C Virus Infection

Completed
2
45
US, RoW
Glecaprevir/Pibrentasvir (G/P), Mavyret
Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections, AbbVie, National Institute of Allergy and Infectious Diseases (NIAID)
Hepatitis C Infection, HIV Infection
05/23
08/23
NCT00031408: Consent for Use of Stored Patient Specimens for Future Testing

Recruiting
N/A
30000
US
Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections, National Institute of Allergy and Infectious Diseases (NIAID)
HIV Infections
12/27
12/27

Download Options